MARKET

SANA

SANA

Sana Biotechnology, Inc.
NASDAQ
3.770
-0.020
-0.53%
Closed 19:59 08/12 EDT
OPEN
3.790
PREV CLOSE
3.790
HIGH
3.870
LOW
3.720
VOLUME
1.82M
TURNOVER
--
52 WEEK HIGH
6.55
52 WEEK LOW
2.610
MARKET CAP
1.13B
P/E (TTM)
-4.9573
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), Pfizer (PFE) and Sana Biotechnology (SANA)
TipRanks · 1d ago
Sana Biotechnology (SANA) Receives a Buy from Wedbush
TipRanks · 1d ago
Sana Biotechnology (SANA) Is Up 13.5% After Narrower Losses And Mayo Clinic Equity Deal - What's Changed
Simply Wall St · 1d ago
Analysts Are Bullish on Top Healthcare Stocks: Sana Biotechnology (SANA), Jade Biosciences (JBIO)
TipRanks · 1d ago
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 2d ago
Sana Biotechnology Q2 Adj. EPS $(0.13) Beats $(0.15) Estimate
Benzinga · 2d ago
Sana Biotechnology reports Q2 EPS (13c), consensus (12c)
TipRanks · 2d ago
Sana Biotechnology Non-GAAP EPS of -$0.13 misses by $0.01
Seeking Alpha · 2d ago
More
About SANA
Sana Biotechnology, Inc. is a biotechnology company focusing on utilizing engineered cells as medicines. It is engaged in developing ex vivo and in vivo cell engineering platforms to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including type 1 diabetes (T1D), oncology, and B cell mediated autoimmune diseases. It develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline products include SC451 and UP421. SC451 is its HIP-edited product candidate for the treatment of type 1 diabetes. SC451 is a pluripotent stem cell (PSC)-derived hypoimmune pancreatic islet cell product candidate for the treatment of diabetes, with an initial focus on T1D. Its ex vivo cell engineering platform is focused on engineering hypoimmune cells that engraft, function, and persist in patients by evading immune rejection.

Webull offers Sana Biotechnology Inc stock information, including NASDAQ: SANA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SANA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SANA stock methods without spending real money on the virtual paper trading platform.